New Zealand Data Sheet

1. PRODUCT NAME

Azamun® 25 mg, 50 mg, 75 mg, 100mg, Film coated tablet

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Azamun 25 mg: each tablet contains 25 mg azathioprine
Azamun 50 mg: each tablet contains 50 mg azathioprine
Azamun 75 mg: each tablet contains 75 mg azathioprine
Azamun 100 mg: each tablet contains 100 mg azathioprine

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Azamun 25 mg: Light yellow, circular, biconvex tablet engraved “AZA” and “25” on one side and plain on the other side.
Azamun 50 mg: Light yellow, circular, biconvex tablet engraved “AZA”’ break-line “50” on one side and plain on the other side.
Azamun 75 mg: Light yellow, circular, biconvex tablet engraved “AZA” and “75” on one side and plain on the other side.
Azamun 100 mg: Light yellow, circular, biconvex tablet engraved “AZA” and “100” on one side and plain on the other side.

The scoreline on Azamun 50 mg is not intended for breaking the tablet.

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Azamun is used as an immunosuppressant anti-metabolite either alone, or more commonly in combination with other agents (usually corticosteroids) and procedures that influence the immune response. The therapeutic effect of Azamun may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and the prolonged use of corticosteroids.

Azamun, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants, such as renal, cardiac and hepatic transplants; and to reduce the corticosteroid requirements of renal transplant recipients.

Azamun is indicated for the treatment of moderate to severe Crohn's disease in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy or patients whose disease is refractory to other standard first-line therapy.
Azamun, either alone or in combination with corticosteroids and/or other medicines and procedures has been used with clinical benefit (which may result in a dose reduction to/or the discontinuation of corticosteroid therapy) in a proportion of patients suffering from:

- severe rheumatoid arthritis
- systemic lupus erythematosus
- dermatomyositis and polymyositis
- auto-immune chronic active hepatitis
- pemphigus vulgaris
- polyarteritis nodosa
- auto-immune haemolytic anaemia
- chronic refractory idiopathic thrombocytopenic purpura
- ulcerative colitis

4.2. Dose and method of administration

Azathioprine is a potent immunosuppressive agent and should be used under the direction of a physician familiar with the risk associated with this type of therapy. The patient should be evaluated carefully and monitored adequately during treatment.

Children considered to be overweight may require doses at the higher end of the dose range and therefore close monitoring of response to treatment is recommended.

Dose

Transplantation: Adults and Children

Depending on the immuno-suppressive regimen adopted, a loading dose of up to 5 mg/kg/day is usually given.

Maintenance dosage may range from 1-4 mg/kg/day orally and must be adjusted according to clinical requirements and haematological tolerance.

Evidence indicates that azathioprine therapy should be maintained indefinitely, even if only low doses are necessary, because of the risk of graft rejection.

Other Conditions: Adults and Children

In general, starting dosage rarely exceeds 3 mg/kg/day, and should be reduced depending on the clinical response (which may not be evident for weeks or months) and haematological tolerance.

When a therapeutic response is evident, consideration should be given to reducing the maintenance dosage to the lowest level compatible with the maintenance of that response. If no improvement occurs in the patient’s condition within three months, consideration should be given to withdrawing Azamun. However, for patients with Crohn’s disease, a treatment duration of at least 12 months should be considered and response to treatment may not be clinically apparent until after 3-4 months of treatment.
The maintenance dosage required may range from less than 1 mg/kg/day to 3 mg/kg/day, depending on the clinical condition being treated and the individual patient response, including haematological tolerance.

Children considered to be overweight may require doses at the higher end of the dose range and therefore close monitoring of response to treatment is recommended.

**Special populations**

**Elderly population**

Particular care should be taken to monitor haematological response and to reduce the maintenance dosage to the minimum required for clinical response (refer to, renal and/or hepatic impairments).

**Renal and/or hepatic impairment**

In patients with renal/or hepatic insufficiency, dosages should be given at the lower end of the normal range (refer to section 4.4).

**TPMT-deficient patients**

Patients with inherited little or no thiopurine S-methyltransferase (TPMT) activity are at increased risk for severe azathioprine toxicity from conventional doses of azathioprine and generally require substantial dose reduction. The optimal starting dose of heterozygous deficient patients has not been established.

Most patients with heterozygous TPMT deficiency can tolerate recommended azathioprine doses, but some may require dose reduction. Genotypic and phenotypic tests of TPMT are available, refer to section 4.4 for further information.

**Interactions requiring specific dose adjustments**

When xanthine oxidase inhibitors, such as allopurinol, and azathioprine are administered concomitantly it is essential that only one quarter of the usual dose of azathioprine is given since allopurinol decreases the rate of catabolism of azathioprine e.g., an azathioprine dose of 100 mg should be reduced to 25 mg (refer to section 4.5).

**Method of Administration**

Azamun tablets should be administered at least 1 hour before or 3 hours after food or milk.

Azamun tablets should be swallowed whole with liquid and must not be divided or chewed.
4.3. Contraindications

- Hypersensitivity to azathioprine or 6-mercaptopurine
- Chickenpox, existing or recent (including recent exposure).
- Herpes zoster.
- Pregnancy should be considered a contraindication

4.4. Special warnings and precautions for use

**Monitoring**

There are potential hazards in the use of Azathioprine. It should be prescribed only if the patient can be adequately monitored for toxic effects throughout the duration of therapy.

Particular care should be taken to monitor haematological response and to reduce the maintenance dosage to the minimum required for clinical response.

It is suggested that during the first 8 weeks of therapy, complete blood counts, including platelets, should be performed weekly or more frequently if the high dosage is used or if severe renal and/or hepatic disorder is present. The blood count frequency may be reduced later in therapy, but it is suggested that complete blood counts are repeated monthly, or at least at intervals of no longer than 3 months.

Patients receiving azathioprine should be instructed to report immediately any evidence of infection, unexpected bruising or bleeding or other manifestations of bone marrow depression. Bone marrow suppression is reversible if azathioprine is withdrawn early enough.

**TPMT testing**

There are individuals with an inherited deficiency of the enzyme thiopurine methyltransferase (TPMT) who may be unusually sensitive to the myelosuppressive effect of azathioprine and prone to developing rapid bone marrow depression following the initiation of treatment with azathioprine. There have been fatal cases of myelosuppression in patients with low or absent TPMT activity treated with thiopurines. This problem could be exacerbated by co-administered with a drug that inhibits TPMT, such as olsalazine, mesalazine or sulphasalazine. Also, a possible association between decreased TPMT activity and secondary leukaemias and myelodysplasia has been reported in individuals receiving 6-mercaptopurine (the active metabolite of azathioprine) in combination with other cytotoxics (refer to section 4.8).

Patients should be tested for TPMT activity before starting azathioprine. TPMT testing cannot substitute for complete blood count monitoring in patients receiving azathioprine. TPMT genotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity (homozygous for non-functional alleles) are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine if conventional doses are given. Alternative therapies may be considered for patients who have low or absent TPMT activity. Azathioprine should be administered with caution to patients having one non-functional allele.
(heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. The dosage of azathioprine may need to be reduced when this agent is combined with other drugs whose primary or secondary toxicity is myelosuppression.

TPMT testing is widely available through pathology laboratories and genetic testing services.

**NUDT15 testing**

Patients with inherited mutated NUDT15 gene are at increased risk for severe thiopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy and generally require substantial dose reduction. The precise mechanism of NUDT 15-associated thiopurine-related toxicity is not understood. Patients of Asian ethnicity are particularly at risk, due to the increased frequency of the mutation in this population. The optimal starting dose for heterozygous or homozygous deficient patients has not been established. Close monitoring of blood count is necessary.

Genotypic and phenotypic testing of NUDT15 variants should be considered before initiating thiopurine therapy in all patients (including paediatric patients) to reduce the risk of thiopurine-related severe leukocytopenia and alopecia, especially in Asian populations.

**Renal and/or hepatic impairment**

Caution is advised during the administration of azathioprine in patients with renal impairment and/or hepatic impairment. Consideration should be given to reducing the dosage in these patients and haematological response should be carefully monitored.

The patient should be instructed to discontinue azathioprine immediately if jaundice becomes apparent.

Limited evidence suggests that azathioprine is not beneficial to patients with a hypoxanthine-guanine-phosphoribosyltransferase deficiency (Lesch-Nyhan syndrome). Therefore, given the abnormal metabolism in these patients, it is not prudent to recommend that these patients should receive azathioprine.

**Mutagenicity**

Chromosomal abnormalities have been demonstrated in both male and female patients treated with azathioprine. It is difficult to assess the role of azathioprine in the development of these abnormalities.

Chromosomal abnormalities, which disappear with time, have been demonstrated in lymphocytes from the offspring of patients treated with azathioprine. Except in extremely rare cases, no overt physical evidence of abnormality has been observed in the offspring of the patients treated with azathioprine.
Azathioprine and long-wave ultraviolet light have been shown to have a synergistic clastogenic effect in patients treated with azathioprine for a range of disorders.

**Effects on fertility**

Relief of chronic renal insufficiency by renal transplantation involving the administration of azathioprine has been accompanied by increased fertility in both male and female transplant recipients (refer to section 4.6).

**Carcinogenicity**

Patients receiving immunosuppressive therapy are at an increased risk of developing non-Hodgkin’s lymphomas and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi’s and non-Kaposi’s) and uterine cervical cancer *in-situ*. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. It has been reported that reduction or discontinuation of immunosuppression may be associated with partial or complete regression of non-Hodgkin’s lymphomas and Kaposi’s sarcomas.

Reports of hepatosplenic T-cell lymphoma in the inflammatory bowel disease population have been received when azathioprine is used in combination with anti-TNF agents.

Patients receiving multiple immunosuppressive agents may be at risk of over-immunosuppression, therefore such therapy should be maintained at the lowest effective level. As is usual for patients with increased risk for skin cancer, exposure to sunlight and UV light should be limited, and patients should wear protective clothing and use a sunscreen with a high protection factor.

**Varicella Zoster Virus infection**

Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts. Therefore, immunisations with live organism vaccines are not recommended (refer to 4.8).

Infection with varicella zoster virus (VZV; chickenpox and herpes zoster) may become severe during the administration of immunosuppressants. Caution should be exercised especially with respect to the following:

Before starting the administration of immunosuppressants, the prescriber should check to see if the patient has a history of VZV. Serologic testing may be useful in determining previous exposure. Patients who have no history of exposure should avoid contact with individuals with chickenpox or herpes zoster. If the patient is exposed to VZV, special care must be taken to avoid patients developing chickenpox or herpes zoster, and passive immunisation with varicella-zoster immunoglobulin (VZIG) may be considered.

If the patient is infected with VZV, appropriate measures should be taken, which may include antiviral therapy and supportive care.
Co-administration of ribavirin and azathioprine is not advised. Ribavirin may reduce efficacy and increase the toxicity of azathioprine.

**Progressive Multifocal Leukoencephalopathy (PML)**

PML, an opportunistic infection caused by the JC virus (a type of human polyomavirus) has been reported in patients receiving azathioprine with other immunosuppressive agents. Immunosuppressive therapy should be withheld at the first sign or symptoms suggestive of PML and appropriate evaluation undertaken to establish a diagnosis (refer to section 4.8).

**Hepatitis B**

Hepatitis B carriers (defined as patients positive for hepatitis B surface antigen [HBsAg] for more than six months), or patients with documented past HBV infection, who receive immunosuppressive drugs are at risk of reactivation of HBV replication, with an asymptomatic increase in serum HBV DNA and ALT levels. Specialist medical literature should be consulted for guidance including prophylactic therapy with oral anti-HBV agents.

**Hypersensitivity**

Several different clinical syndromes, which appear to be idiosyncratic manifestations of hypersensitivity, have been described occasionally following administration of azathioprine (refer to section 4.8). Clinical features include general malaise, dizziness, nausea, vomiting, diarrhoea, fever, rigours, exanthema, rash, erythema nodosum, vasculitis, myalgia, arthralgia, hypotension, renal dysfunction, hepatic dysfunction and cholestasis.

4.5. Interaction with other medicines and other forms of interaction

**Allopurinol/ oxipurinol/ thiopurinol**

Xanthine oxidase activity is inhibited by allopurinol, oxipurinol and thiopurinol which results in reduced conversion of biologically active 6-thioguanosine to biologically inactive 6-thiouric acid. When allopurinol, oxipurinol and/or thiopurinol are given concomitantly with 6-mercaptopurine or azathioprine, the dose of 6-mercaptopurine and azathioprine should be reduced to one quarter of the usual dose, refer to section 4.2.

**Neuromuscular blocking agents**

Azathioprine can potentiate the neuromuscular blockade produced by depolarising agents such as succinylcholine and can reduce the blockade produced by non-depolarising agents such as tubocurarine. There is considerable variation in the potency of this interaction.

**Anticoagulants**

Inhibition of the anticoagulant effect of warfarin and acenocoumarol has been reported when co-administered with azathioprine. Therefore, higher doses of the anticoagulant may be needed. It is recommended that coagulation tests are closely monitored when anticoagulants are concurrently administered with azathioprine.
Cytostatic/ myelosuppressive agents

Where possible, concomitant administration of cytostatic drugs, or drugs which may have a myelosuppressive effect, such as penicillamine, should be avoided. There are conflicting clinical reports of interactions, resulting in serious haematological abnormalities, between azathioprine and co-trimoxazole.

There has been a case report suggesting that haematological abnormalities may develop due to the concomitant administration of azathioprine and captopril.

It has been suggested that cimetidine and indomethacin may have myelosuppressive effects which may be enhanced by concomitant administration of azathioprine.

Aminosalicylates

As there is in vitro and in vivo evidence that aminosalicylate derivatives (e.g. olsalazine, mesalazine or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent Azamun therapy.

Methotrexate

Methotrexate (20 mg/m² orally) increased 6-mercaptopurine AUC by approximately 31% and methotrexate (2 or 5 g/m² intravenously) increased 6-mercaptopurine AUC by 69 and 93% respectively. Therefore, when azathioprine is administered concomitantly with high dose methotrexate, the dose should be adjusted to maintain a suitable white blood cell count.

Other interactions

Furosamide has been shown to impair the metabolism of azathioprine by human hepatic tissue in vitro. The clinical significance is unknown.

Vaccines

The immunosuppressive activity of azathioprine could result in an atypical and potentially deleterious response to live vaccines and so the administration of live vaccines to patients receiving azathioprine therapy is contraindicated on theoretical grounds.

A diminished response to killed vaccines is likely and such a response to hepatitis B vaccine has been observed among patients treated with a combination of azathioprine and corticosteroids. A small clinical study has indicated that standard therapeutic doses of azathioprine do not deleteriously affect the response to a polyvalent pneumococcal vaccine, as assessed on the basis of mean anti-capsular specific antibody concentration.

Ribavirin

Ribavirin inhibits the enzyme, inosine monophosphate dehydrogenase (IMPDH), leading to a lower production of the active 6-thioguanine nucleotides. Severe myelosuppression has been
reported following concomitant administration of azathioprine and ribavirin; therefore, co-
administration is not advised.

4.6. Fertility, pregnancy and lactation

**Pregnancy**

Pregnancy category D

Azathioprine should not be given to patients who are pregnant or likely to become pregnant in
the near future without careful assessment of risk versus benefit.

Evidence of the teratogenicity of azathioprine in man is equivocal. As with all cytotoxic
chemotherapy, adequate contraceptive precautions should be advised when either partner is
receiving azathioprine.

There have been reports of premature birth and low birth weight following maternal exposure to
azathioprine, particularly in combination with corticosteroids. There have also been reports of
spontaneous abortion following either maternal or paternal exposure.

Azathioprine and/or its metabolites have been found in low concentrations in foetal blood and
amniotic fluid after maternal administration of azathioprine.

Leucopenia and/or thrombocytopenia have been reported in the proportion of neonates whose
mothers took azathioprine throughout their pregnancies. Extra care in haematological monitoring
is advised during pregnancy.

**Breast-feeding**

6-Mercaptopurine has been identified in the colostrum and breastmilk of women receiving
azathioprine treatment.

4.7. Effects on ability to drive and use machines

There are no data on the effect of azathioprine on driving performance or the ability to operate
machinery. A detrimental effect on these activities cannot be predicted from the pharmacology
of the drug.

4.8. Undesirable effects

For this product, there is no modern clinical documentation which can be used as support for
determining the frequency of undesirable effects. Undesirable effects may vary in their incidence
depending on the indication. The following convention has been utilised for the classification of
frequency: Very common ≥1/10, common ≥1/100, <1/10, uncommon ≥1/1000 and <1/100, rare
≥1/10,000 and <1/1000, very rare <1/10,000.

**Infections and infestations**
Very common: viral, fungal and bacterial infections in transplant patients receiving azathioprine in combination with other immunosuppressants.

Uncommon: viral, fungal and bacterial infections in other patient populations.

Very rare: cases of JC virus-associated PML have been reported following the use of azathioprine in combination with other immunosuppressants (refer to section 4.4).

Patients receiving azathioprine alone or in combination with other immunosuppressants, particularly corticosteroids, have shown increased susceptibility to viral, fungal and bacterial infections, including severe or atypical infection and reactivation with VZV, hepatitis B and other infectious agents (refer to section 4.4).

Neoplasms benign and malignant (including cysts and polyps)

Rare: Neoplasms including non-Hodgkin's lymphomas, skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ, acute myeloid leukaemia and myelodysplasia (refer to section 4.4).


The risk of developing non-Hodgkin's lymphomas and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ, is increased in patients who receive immunosuppressive drugs, particularly in transplant recipients receiving aggressive treatment and such therapy should be maintained at the lowest effective levels. The increased risk of developing non-Hodgkin's lymphomas in immunosuppressed rheumatoid arthritis patients compared with the general population appears to be related at least in part to the disease itself.

There have been rare reports of acute myeloid leukaemia and myelodysplasia (some in association with chromosomal abnormalities).

Blood and lymphatic system disorders

Very common: depression of bone marrow function; leucopenia.
Common: thrombocytopenia.

Uncommon: anaemia.

Rare: agranulocytosis, pancytopenia, aplastic anaemia, megaloblastic anaemia, erythroid hypoplasia.

Azathioprine may be associated with a dose-related, generally reversible, depression of bone marrow function, most frequently expressed as leucopenia, but also sometimes as anaemia and thrombocytopenia and rarely as agranulocytosis, pancytopenia and aplastic anaemia. These occur
particularly in patients predisposed to myelotoxicity, such as those with TPMT deficiency and renal or hepatic insufficiency and in patients failing to reduce the dose of azathioprine when receiving concurrent allopurinol therapy.

Reversible, dose-related increases in mean corpuscular volume and red cell haemoglobin content have occurred in association with Azamun therapy.

Megaloblastic bone marrow changes have also been observed but severe megaloblastic anaemia and erythroid hypoplasia are rare.

**Immune system disorders**

Uncommon: hypersensitivity reactions.

Very Rare: Stevens-Johnson syndrome and toxic epidermal necrolysis.

Several different clinical syndromes, which appear to be idiosyncratic manifestations of hypersensitivity, have been described occasionally following administration of azathioprine. Clinical features include general malaise, dizziness, nausea, vomiting, diarrhoea, fever, rigours, exanthema, rash, erythema nodosum, vasculitis, myalgia, arthralgia, hypotension, renal dysfunction, hepatic dysfunction and cholestasis.

In many cases, re-challenge has confirmed an association with azathioprine.

Immediate withdrawal of azathioprine and institution of circulatory support where appropriate have led to recovery in the majority of cases.

Other marked underlying pathology has contributed to the very rare deaths reported.

Following a hypersensitivity reaction to azathioprine, the necessity for continued administration of azathioprine should be carefully considered on an individual basis.

**Respiratory, thoracic and mediastinal disorders**

Very rare: reversible pneumonitis

**Gastrointestinal disorders**

Common: nausea.

Uncommon: pancreatitis.

Very rare: colitis, diverticulitis and bowel perforation reported in transplant population, severe diarrhoea in inflammatory bowel disease population.

A minority of patients experience nausea when first given azathioprine. This appears to be relieved by administering the tablets after meals.
Serious complications, including colitis, diverticulitis and bowel perforation, have been described in transplant recipients receiving immunosuppressive therapy. However, the aetiology is not clearly established, and high-dose corticosteroids may be implicated. Severe diarrhoea, recurring on rechallenge, has been reported in patients treated with azathioprine for inflammatory bowel disease. The possibility that exacerbation of symptoms might be drug-related should be borne in mind when treating such patients.

Pancreatitis has been reported in a small percentage of patients on azathioprine therapy, particularly in renal transplant patients and those diagnosed as having inflammatory bowel disease. There are difficulties in relating the pancreatitis to the administration of one particular drug, although rechallenge has confirmed an association with azathioprine on occasions.

**Hepato-biliary disorders**

Uncommon: cholestasis and deterioration of liver function tests.

Rare: life-threatening hepatic damage.

Cholestasis and deterioration of liver function have occasionally been reported in association with azathioprine therapy and are usually reversible on withdrawal of therapy. This may be associated with symptoms of a hypersensitivity reaction.

Rare, but life-threatening hepatic damage associated with chronic administration of azathioprine has been described primarily in transplant patients. Histological findings include sinusoidal dilatation, peliosis hepatitis, veno-occlusive disease and nodular regenerative hyperplasia. In some cases, withdrawal of azathioprine has resulted in either a temporary or permanent improvement in liver histology and symptoms.

**Skin and subcutaneous tissue disorders**

Rare: alopecia.

Hair loss has been described on a number of occasions in patients receiving azathioprine and other immunosuppressive agents. In many instances, the condition resolved spontaneously despite continuing therapy. The relationship between alopecia and azathioprine treatment is uncertain.

**Other Adverse Effects**

Other adverse reactions include sores in the mouth and on the lips, meningitis, formication, acute febrile neutrophilic dermatosis (Sweet’s Syndrome), exacerbation of myasthenia gravis and dermatomyositis and alterations in the senses of smell or taste.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/)

4.9. Overdose

Symptoms

Unexplained infection, ulceration of the throat, bruising and bleeding are the main signs of overdosage with azathioprine and result from bone marrow depression which may be maximal after 9 - 14 days. These signs are more likely to be manifest following chronic overdosage, rather than after a single acute overdose. There has been a report of a patient who ingested a single overdose of 7.5 g of azathioprine. The immediate toxic effects of the overdose were nausea, vomiting and diarrhoea, followed by mild leucopenia and mild abnormalities in liver function. Recovery was uneventful.

Treatment

There is no specific antidote. The value of dialysis in patients who have taken an overdose of azathioprine is not known, though azathioprine is partially dialysable.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Pharmacotherapeutic group: immunosuppressant; ATC code: L04AX01
Azathioprine is an imidazolyl derivative of 6-mercaptopurine (6-MP). It is rapidly broken down in vivo into 6-MP and a methylnitroimidazole moiety. The 6-MP readily crosses the cell membrane and is converted intracellularly into a number of purine thioanalogues, which include the main active nucleotide, thioinosinic acid. The rate of conversion varies from one person to another.

Nucleotides do not traverse cell membranes and therefore do not circulate in body fluids. Irrespective of whether it is given directly or is derived from in vivo from azathioprine, 6-MP is eliminated mainly as the inactive oxidised metabolite thiouric acid.

This oxidation is brought about by xanthine oxidase, an enzyme which is inhibited by allopurinol. The activity of the methylnitroimidazole moiety has not been defined clearly. However, in several systems it appears to modify the activity of azathioprine as compared with that of 6-MP.
Determinations of plasma concentrations of azathioprine or 6-MP have no prognostic value as regard effectiveness or toxicity of these compounds.

**Mechanism of action**

While the precise modes of action remain to be elucidated, some suggested mechanisms include:

1. the release of 6-MP which acts as a purine antimetabolite.
2. the possible blockade of -SH groups by alkylation.
3. the inhibition of many pathways in nucleic acid biosynthesis, hence preventing proliferation of cells involved in determination and amplification of the immune response.
4. damage to deoxyribonucleic acid (DNA) through incorporation of purine thio-analogues.

Because of these mechanisms, the therapeutic effect of azathioprine may be evident only after several weeks or months of treatment.

**5.2. Pharmacokinetic properties**

Azathioprine appears to be well absorbed from the upper gastrointestinal tract.

Studies in mice with $^{35}$S-azathioprine showed no unusually large concentration in any particular tissue, but there was very little $^{35}$S found in the brain.

Plasma levels of azathioprine and 6-mercaptopurine do not correlate well with the therapeutic efficacy or toxicity of azathioprine.

**5.3. Preclinical safety data**

**Teratogenicity**

Studies in pregnant rats, mice and rabbits using azathioprine in dosages from 5-15 mg/kg body weight/day over the period of organogenesis have shown varying degrees of foetal abnormalities.

Teratogenicity was evident in rabbits at 10 mg/kg bodyweight/day.

**6. PHARMACEUTICAL PARTICULARS**

**6.1. List of excipients**

Azamun contains cellulose microcrystalline, mannitol, povidone, maize starch, croscarmellose sodium, sodium stearyl fumarate in the tablet core. The tablet coating contains Opadry clear OY-7240 (macrogol 400 and hypromellose).

**6.2. Incompatibilities**

Not known.
6.3. Shelf life

36 months.

6.4. Special precautions for storage

Azamun 25 mg and 50 mg: Store at or below 30°C and protect from light and moisture.
Azamun 75 mg and 100 mg: Store at or below 25°C and protect from light and moisture.

6.5. Nature and contents of container

Azamun 25 mg: 30, 60 and 100 tablets in PVC/PVDC-Aluminium foil blister strips.
Azamun 50 mg, 75 mg, 100 mg: 100 tablets in PVC/PVDC-Aluminium foil blister strips.

Not all strengths or pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

Any unused medicine or waste material should be disposed of in accordance with local requirements.

7. MEDICINE SCHEDULE

Prescription Medicine

8. SPONSOR

Douglas Pharmaceuticals Ltd
P O Box 45 027
Auckland 0651
New Zealand
Phone: (09) 835 0660

9. DATE OF FIRST APPROVAL

Azamun 50 mg: 13 August 1998

Azamun 25 mg, 75 mg, 100 mg: 26 June 2014

10. DATE OF REVISION OF THE TEXT

11 October 2022

Summary table of changes
<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4</td>
<td>Hypersensitivity information from 4.8 added, as per Medsafe request</td>
</tr>
<tr>
<td>4.8</td>
<td>Erythema nodosum added as an ADR, as per Medsafe request</td>
</tr>
</tbody>
</table>